United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi consumer healthcare - fexofenadine hydrochloride - oral tablet - 30mg

Malta - English - Medicines Authority

sanofi malta limited level2, fort business centre, mriehel bypass, birkirkara, malta - fexofenadine hydrochloride - film-coated tablet - fexofenadine hydrochloride 30 mg - antihistamines for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - fexofenadine hydrochloride - film-coated tablet - 30 milligram(s) - antihistamines for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

opella healthcare france sas t/a sanofi - fexofenadine hydrochloride - film-coated tablet - 30 milligram(s) - antihistamines for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - fexofenadine hydrochloride - film-coated tablet - 120 milligram(s) - other antihistamines for systemic use; fexofenadine

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: poloxamer; xylitol; sucrose; propylene glycol; monobasic sodium phosphate monohydrate; propyl hydroxybenzoate; disodium edetate; purified water; butyl hydroxybenzoate; dibasic sodium phosphate heptahydrate; xanthan gum; titanium dioxide; flavour - relief of symptoms associated with seasonal allergic rhinitis and allergic rhinitis in adults and children from 2 years of age. relief of symptoms associated with urticaria in adults and children from 6 months of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 30 mg - tablet, film coated - excipient ingredients: titanium dioxide; pregelatinised maize starch; hypromellose; macrogol 400; colloidal anhydrous silica; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; iron oxide red; iron oxide yellow - relief of symptoms associated with seasonal allergic rhinitis, allergic rhinitis or urticaria in adults and children from 6 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - pseudoephedrine hydrochloride, quantity: 120 mg; fexofenadine hydrochloride, quantity: 60 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; pregelatinised maize starch; carnauba wax; colloidal anhydrous silica; stearic acid; macrogol 8000; hypromellose; macrogol 400 - for the relief of the symptoms of seasonal allergic rhinitis with nasal congestion when both the antiallergic properties of fexofenadine hydrochloride and the decongestant activity of pseudoephedrine hydrochloride are required.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: macrogol 400; titanium dioxide; hypromellose; povidone; pregelatinised maize starch; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; colloidal anhydrous silica; iron oxide yellow; iron oxide red - relief of symptoms associated with allergic rhinitis in adults and children aged 12 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 120 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 400; titanium dioxide; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; povidone; colloidal anhydrous silica; pregelatinised maize starch; iron oxide yellow; iron oxide red - relief of symptoms associated with seasonal allergic rhinitis for adults and children aged 12 years and over.